Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 820

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 820
---
stockdividends(in thousands) |    |
| Series 1                |     |        | 1,929 |     |                  | 58.00 |     |                                         | 33 |     |                                              | 23 |
| Series 2                |     |        |   219 |     |                  | 60.70 |     |                                         |  4 |     |                                              |  3 |
| Series 3                |     |        |   296 |     |                  | 57.50 |     |                                         |  5 |     |                                              |  4 |
|                         |     |        | 2,444 |     |                  |       |     |                                         | 42 |     |                                              | 30 |

| 8 | Supplementary statement of cash flows information |

The Company incurred the following non-cashinvesting and financing transactions (in thousands):

|                                                         |     | Six months endedDecember 31, |     |     |       |     |
|                                                         |     |                        2023$ |     |     | 2022$ |     |
| Series C Preferred Stock common stock dividend (note 7) |     |                              | 173 |     |       | 362 |
| Non-cashissue costs (note 7)                            |     |                              |   — |     |       | 289 |
| Subscriptions receivable (note 7)                       |     |                              | 103 |     |       |   — |
| Equipment additions reclassified from prepaid expenses  |     |                              |   — |     |       | 447 |
| Income taxes paid                                       |     |                              |   — |     |       |   — |
| Interest paid                                           |     |                              |   — |     |       |   — |

F-64

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 9 | Financial instruments |

The Company’s financial instruments are measured at fair value as determined by using the fair value hierarchy for inputs that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Un